Co-Intelligence Platform

Spot Your Tailored
505(b)(2)Brand ExtensionRepurposingReformulationHybrid Pathway
Opportunities in Days, Not Months

Replace months of manual commercial, regulatory, IP, clinical, and formulation analysis with structured, evidence-backed opportunities your team can act on immediately.

Schedule a Customized Demo Explore the Platform
Client Success
Months → Days
Screening velocity
300+
Opportunities evaluated
10×
Faster than manual screening
rethink Tx · Co-Intelligence for Specialty Pharma

Surface overlooked molecules, indications, formulations, and pathway combinations at scale.

Opportunity Discovery EngineSurface opportunities tailored to your capabilities, criteria, and strategy
Risk-Gated Pipeline BuilderConvert ideas into a staged pipeline aligned to your budget and risk appetite
Opportunity LibraryEvidence-backed opportunities filtered by pathway, feasibility, and strategic fit

Assess feasibility across all evaluation dimensions simultaneously.

Cross-Functional Feasibility ScoringMulti-dimensional feasibility across 50+ regulatory, IP, clinical, CMC, and commercial parameters
Regulatory Pathway MapsViable regulatory routes based on RLD, formulation delta, and FDA precedent
Bridging Strategy RationaleStructured scientific rationale for studies bridged, waived, or relied upon from the RLD

Identify optimal development paths by weighing risk, timing, evidence burden, and value.

Option Path ModellingCompare scenarios across timeline, investment, clinical burden, and expected value
Evidence Gap & Workaround OptimizerIdentify gaps, vulnerabilities, and workaround strategies before committing capital
Cross-Pathway Strategy ComparisonQuantified comparison: 505(b)(2) vs. Suitability Petition vs. Hybrid Application

Deliver review-ready development plans and stakeholder-ready materials.

Source-Linked Development PlansIntegrated plans traceable to FDA guidance and precedent approvals
FDA Interaction PackagesPre-IND, Type B, and meeting packages with precedent-backed arguments
Decision, Board & Deal DossiersGo/No Go, board, licensing, and investment materials backed by evidence

Unified intelligence layer behind every portfolio decision.

Unified Pharma DatasetSearchable molecule, regulatory, IP, clinical, labeling, and approval intelligence
Reference Product & Precedent DossiersDeep RLD profiles with approval history, patent estate, and known precedent
Portfolio Monitoring HubTrack competitive movement, PIV challenges, clinical activity, and risk signals
FDA · EMA · MHRA
On-Premise
Platform

Co-intelligence for the entire
opportunity lifecycle

Co-intelligence is when functional expertise works with an intelligence layer to amplify certainty and turn fragmented analysis into confident, defensible decisions.

Expert Judgment, Amplified
Ideation
Opportunity Discovery Engine
Surface opportunities, not just data
Risk-Gated Pipeline Builder
Aligned to budget & risk appetite
Opportunity Library
Evidence-ranked, not opinion-based
Validation
Cross-Functional Feasibility
Multi-dimensional view in hours
Regulatory Pathway Maps
Precedent-based pathways
Bridging Strategy Rationale
Pre-built regulatory argument
Optimization
Option Path Modelling
See trade-offs before committing
Evidence Gap Optimizer
Reduce risk before lock-in
Cross-Pathway Comparison
Data-driven path selection
Confirmation
Source-Linked Dev Plans
Evidence-linked, not narrative
FDA Interaction Packages
Precedent-backed arguments
Decision & Deal Dossiers
Evidence-backed decisions
Your Expertise × Intelligence Layer
Agents & Skills

AI that researches, cross-references, scores & drafts

Configured & Autonomous AgentsCollaborative & Autonomous WorkflowsFeedback Loops & Output ChainsAlerts & Recommendations
Catalogues

Structured domain knowledge for pharma development

MoleculesIndicationsPathwaysDevices & TechnologiesAnnotationsDeficienciesDomain ContextsEnablers & Capabilities
Data

Curated regulatory, scientific & proprietary sources

FDA Orange BookDailyMedDrugs @ FDAClinicalTrials.govUSPTO PatentsPubMedEMCMHRAIP IntelligenceMarket DataClient Proprietary Data
The Intelligence Layer
Powered by The Intelligence Layer. AI agents, structured catalogues, and curated regulatory, scientific, and proprietary data sources working together to amplify your team's expertise.
Deployment

Deployed within your environment

Built for regulated pharma environments with configurable workflows, proprietary data integration, and secure deployment options.

On-Premises & Private Cloud
Full control over data residency and access within your infrastructure.
Proprietary Data Integration
Internal pipeline data, historical assessments, and institutional records with full data isolation.
Configurable Frameworks
Tailor scoring models, evaluation criteria, and workflows to your specific process.
Why rethink

The compounding cost of
manual portfolio intelligence

The current approach has structural limitations that compound with every quarter of delay.

Challenge · Shift · Urgency
#
Challenge Today
With rethink
Why Now
1
Fragmented Evidence
Synthesized Intelligence
Accelerated filings
2
Manual Screening
Scalable Ideation
Patent cliffs demand speed
3
Assumption-Driven Plans
Precedent-Grounded Validation
Regulators favor structured evidence
4
Sequential Review
Parallel Assessment
Expert talent is scarce
5
Static Analysis
Compounding Knowledge
Delay compounds cost
Client Outcomes

Results from the first rethink client engagement.

Months → Days
Screening Velocity
Full cross-functional screening cycle compressed
First client engagement, 2024
300+
Opportunities Surfaced
Scored opportunities from a single therapeutic scan
First client engagement, 2024
50+
Evaluation Parameters
Across regulatory, IP, clinical, CMC & commercial
Platform capability
30+
Development-Ready Strategies
Structured with full cross-functional alignment
First client engagement, 2024
Stakeholders

Built for the teams who advance
development opportunities

From first screen to IND-ready strategy, rethink amplifies the experts who make portfolio decisions.

Who uses it
Portfolio Manager
Screens, compares & decides
Business Development
Target screening & diligence
Commercial Strategy
Market & competitive assessment
Regulatory Affairs
Pathway strategy & precedent mapping
IP & Patent Strategy
Patent landscape & FTO analysis
Formulation & CMC
Reformulation feasibility
Clinical Development
Study design & evidence gaps
Organizations we serve
Large Pharma
Turn existing assets into new lifecycle and brand-extension opportunities.
Specialty Pharma
Build a sharper, evidence-backed specialty pharma pipeline faster.
Pharma Investors
Evaluate target assets with structured diligence at a depth and speed manual processes cannot match.
Get Started

See what your next opportunity looks like
when every function evaluates it simultaneously

Bring us a molecule, an indication, or a formulation concept and we'll take it from initial screening through development-ready strategy, tailored to your criteria.

The Opportunity Lifecycle, powered by rethink
Ideate
→
Validate
→
Optimize
→
Confirm
Schedule a Customized Demo